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ABSTRACT  35 
The cytokine IL-6 controls the survival, proliferation and effector characteristics of lymphocytes through 36 
activation of the transcription factors STAT1 and STAT3. While STAT3 activity is an ever-present feature 37 
of IL-6 signaling in CD4+ T cells, prior T-cell receptor activation limits the IL-6 control of STAT1 in effector 38 
and memory populations. Here we show that STAT1 phosphorylation in response to IL-6 was regulated 39 
by protein tyrosine phosphatases (PTPN2, PTPN22) expressed in response to the activation of naïve CD4+ 40 
T cells. Transcriptomic and chromatin immunoprecipitation-sequencing of IL-6 responses in naïve and 41 
effector memory CD4+ T cells showed how the suppression of STAT1 activation shaped the functional 42 
identity and effector characteristics of memory CD4+ T cells. Thus, protein tyrosine phosphatases induced 43 
by activation of naïve T cells determined the way activated or memory CD4+ T cells sensed and 44 
interpreted cytokine signals.  45 
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Naïve, activated and memory T cells display differences in their ability to respond to antigen. These 46 
include changes in proliferation, survival, sensitivity to antigen, dependence on co-stimulatory signals 47 
and alterations in T cell homing1. Cytokines responsible for the control of these activities often signal 48 
through receptor-associated Janus kinases (Jak proteins) that regulate cytoplasmic transcription factors 49 
termed signal transducers and activators of transcription (STAT)2. Thus, the Jak-STAT pathway senses and 50 
interprets environmental signals essential for proliferation and functional identity2. Here, we examined 51 
whether cytokine cues delivered by the Jak-STAT pathway can be adapted to fine-tune the effector 52 
properties of individual CD4+ T cell subsets.  53 
Studies of infection, inflammation, autoimmunity and cancer demonstrate that the cytokine IL-6 is 54 
essential for the generation of adaptive immunity3. Activities include the maturation and maintenance of 55 
antibody secreting B cells, and responses that shape the effector characteristics of CD4+ T helper (TH) 56 
cells3. In this regard, mice lacking IL-6 often show deficiencies in T cell effector function and memory 57 
recall4, 5, 6, 7, 8, 9. Studies also suggest that CD4+ T cells display differences in IL-6 responsiveness that may 58 
reflect the activation status of the T cell7, 10, 11, 12. How these differences arise is currently unclear.  59 
The receptor complex responsible for IL-6 signaling consists of a type-1 cytokine receptor (IL-6R, CD126) 60 
and a signal-transducing β-receptor (gp130, CD130) subunit3. IL-6R is shed in response to CD4+ T cell 61 
activation, and inflammatory T cells from sites of disease often display low IL-6R expression7, 10, 12, 13, 14, 15, 62 
16, 17. IL-6 activates the latent transcription factors STAT1 and STAT33. IL-6 control of STAT3 is essential for 63 
T cell recruitment and survival and the maintenance of activated T cells within inflamed tissues11, 14, 16. 64 
These STAT3-driven responses include the transactivation of anti-apoptotic regulators and genes that 65 
determine the effector or regulatory characteristic of CD4+ T cells3, 11, 18. In contrast, IL-6 activation of 66 
STAT1 plays a more regulatory role and often determines the transcriptional output of STAT318, 19, 20, 21. 67 
These studies illustrate a complex interplay between STAT1 and STAT3, and emphasize how STAT1 68 
signaling may shape the biological properties of IL-618, 20, 21, 22, 23, 24. Significantly, CD4+ T cell activation has 69 
been shown to alter IL-6 signaling through STAT19, 11. Here we show that STAT1 phosphorylation in 70 
response to IL-6 is suppressed in activated and memory CD4+ T cells and identified protein tyrosine 71 
phosphatases as regulators of STAT1 activity. Our data further showed how this re-programming 72 
mechanism may influence the way effector memory CD4+ T cells sense and interpret IL-6 signals in 73 
disease.  74 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
4 
RESULTS 75 
Infiltrating synovial CD4+ T cells have altered IL-6-mediated STAT1 activation  76 
Previous studies suggest that CD4+ T cell activation alters cytokine signaling through the Jak-STAT 77 
pathway4, 9, 11. To further these findings we established antigen-induced arthritis (AIA) in C57Bl/6 wild-78 
type mice through immunization with methylated BSA (mBSA). Histological joint sections from day 10 of 79 
AIA were evaluated for tyrosine phosphorylated STAT1 and STAT3 (hereafter pY-STAT1 and pY-STAT3) 80 
using immunofluorescence (Fig. 1a). While pY-STAT3 co-localized with CD3+ T cells, pY-STAT1 showed 81 
weak co-localization with the CD3 stain (Fig. 1a). To verify these observations, CD4+ T cells were isolated 82 
at day 10 of AIA from the inflamed synovium of wild-type mice and stimulated ex vivo with IL-6 83 
(20ng/ml). When compared to IL-6-treated CD4+CD25−CD44loCD62LhiCD127hi naïve T cells (TN cells) from 84 
the spleen of wild-type mice, intracellular flow cytometry showed that synovial CD4+ T cells displayed 85 
reduced pY-STAT1 staining (Fig. 1b). Both CD4+ T cell populations displayed comparable pY-STAT3 86 
responses to IL-6 (Fig. 1b). To test whether prior antigenic challenge with mBSA restricted the ability of 87 
IL-6 to signal through STAT1, we extracted total CD4+ T cells from the inguinal draining lymph nodes of 88 
wild-type mice immunized with mBSA, stimulated them ex vivo for 30 min with 20ng/ml IL-6 and 89 
monitored changes in pY-STAT1 and pY-STAT3 by intracellular flow cytometry. When compared to wild-90 
type CD4+ T cells from the inguinal lymph node of non-challenged mice, CD4+ T cells from mBSA-91 
immunized mice showed impaired pY-STAT1 detection in response to IL-6 (Fig. 1c). This reduction in 92 
pY-STAT1 was particularly evident in activated or memory CD4+ T cells (Fig. 1c). 93 
STAT1 is an important determinant of T cell effector function20, 21, 22. We therefore used quantitative PCR 94 
to evaluate the effector characteristics of CD4+ T cells from wild-type mice with AIA. Analysis was 95 
performed on CD4+ TN cells and CD4+CD25−CD44hiCD62LloCD127int-hi effector memory T cells (TEM cells) 96 
from the inguinal lymph nodes of wild-type mice with AIA. Ahr, Il21, Rorgt, Il17a, Ifng and Stat3 were all 97 
highly expressed in CD4+ TEM cells compared to CD4+ TN cells (Fig. 1d). In contrast, the expression of 98 
Socs3, a negative regulator of Jak-STAT signaling, remained comparable in both CD4+ T cell populations 99 
(Fig. 1d). In addition, intracellular cytokine staining of CD4+ TN and CD4+ TEM cells showed that CD4+ TEM 100 
cells generated increased amounts of IL-21 (Fig. 1e and Supplementary Fig. 1a). Thus, CD4+ TN and CD4+ 101 
TEM cells showed differences in IL-6 responsiveness. 102 
Control of STAT1 activity is not determined by IL-6R signaling in CD4+ T cells 103 
To determine if T cell subsets display different IL-6 signaling properties, splenic CD4+ TN cells, 104 
CD4+CD25−CD44hiCD62LhiCD127hi central memory T cells (TCM cells), CD4+CD25−CD44loCD62LloCD127lo-int 105 
effector T cells (TEff cells) and CD4+ TEM cells were purified from wild-type mice. These populations 106 
showed differences in IL-6R and gp130 expression, but displayed a similar transient activation of 107 
pY-STAT3 in response to IL-6 (Fig. 2a and Supplementary Fig. 1b). A strong induction of pY-STAT1 was 108 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
5 
observed in IL-6-treated CD4+ TN cells, while CD4+ TCM, TEff and TEM cells showed impaired pY-STAT1 109 
activation (Fig. 2a). A similar regulation of pY-STAT1 was also observed in human CD4+ T cells 110 
(Supplementary Fig. 1c). 111 
Given that activation-induced shedding of IL-6R may affect IL-6 receptor signaling, we investigated the 112 
IL-6 control of pY-STAT1 and pY-STAT3 in splenic CD4+ TN, TCM, TEff and TEM cells from wild-type and Il6ra-/- 113 
mice. IL-6 signaling in Il6ra-/- CD4+ T cells was triggered by IL-6 trans-signaling using an IL-6-sIL-6R chimeric 114 
fusion protein (HDS)7, 8. Il6ra-/- CD4+ T cells were not activated by IL-6 alone, but responded to an 115 
equimolar concentration of HDS, and all Il6ra-/- CD4+ T cells showed increased pY-STAT3 following HDS 116 
stimulation (Fig. 2b). While HDS induced pY-STAT1 in Il6ra-/- CD4+ TN cells, changes in pY-STAT1 was not 117 
seen in HDS-treated CD4+ TCM, TEff and TEM cells from Il6ra-/- mice (Fig. 2b). Thus, the loss of STAT1 118 
signaling in activated CD4+ T cells is independent of changes in IL-6R regulation. A similar pattern of 119 
pY-STAT1 regulation was noted in wild-type CD4+ T cells stimulated with IL-27 or IFN-γ (Fig. 2c and 120 
Supplementary Fig. 2d), suggesting the control of STAT1 phosphorylation was not unique to IL-6.  121 
TCR activation regulates IL-6R signaling in CD4+ T cells  122 
To investigate whether prior TCR engagement contributed to the changes in STAT1 activation in 123 
activated or memory CD4+ T cells we compared IL-6 signaling in CD4+ TN cells and CD4+ T cells previously 124 
activated with antibodies against CD3 and CD28. Wild-type CD4+ TN cells were cultured for 72h with 125 
antibodies against CD3 and CD28 followed by a 48h culture in fresh media, in the absence of exogenous 126 
stimulation. This rest period restored the surface expression of IL-6R on these TCR-experienced effector-127 
like CD4+ T cells (TEXP cells; Supplementary Fig. 2a). While IL-6 stimulation of CD4+ TEXP cells induced 128 
pY-STAT3, the activation of pY-STAT1 was minimal when compared to the IL-6-dependent induction of 129 
pY-STAT1 in CD4+ TN cells (Supplementary Fig. 2b,c), indicating CD4+ T cell activation altered the 130 
subsequent activation of STAT1 by IL-6. 131 
To test if TCR signaling altered the IL-6-induced activation of STAT1, we generated CD4+ TEXP cells from 132 
wild-type CD4+ TN cells using varying concentrations of co-stimulatory CD3 (0.1-10 μg/ml) and CD28 (0.5-133 
15 μg/ml) antibodies (Supplementary Fig. 3a) and stimulated the expanded CD4+ TEXP cells with IL-6. The 134 
IL-6-dependent induction of pY-STAT3 was not affected by differences in antibody concentration. 135 
However the suppression of pY-STAT1 in response to IL-6 was sensitive to anti-CD3 antibody treatment 136 
with increasing doses of antibody leading to a repression of pY-STAT1 (Supplementary Fig. 3a). Thus, TCR 137 
signaling affected the inhibition of pY-STAT1 by IL-6.  138 
We next determined whether changes in STAT1 activation altered the transcriptional output of IL-6. CD4+ 139 
TN, TEXP and TEM cells were stimulated for 6 h with IL-6 followed by transcriptomic analysis. This time point 140 
was selected based on the temporal profile of pY-STAT1 and pY-STAT3 detection (Fig. 2a), and the 141 
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optimal expression of STAT-target genes (Ahr, Bcl3, Bcl6, Kat2b, Il10, Il21, Pim1, Stat3), as determined by 142 
Q-PCR (Supplementary Fig. 3b). CD4+ TN, TEXP, and TEM cells expressed a series of genes that were both 143 
common (e.g., Socs1, Sbno2, Bcl6) and unique (e.g., CD4+ TN – Cxcr1, Tnfrsf14; CD4+ TEXP – Gzma, Ajuba; 144 
CD4+ TEM – Ahr, Il10, Il21) to all three CD4+ T cell populations (Fig. 2d and Supplementary Fig. 3c). The 145 
number of transcripts enhanced by IL-6 in CD4+ TEXP cells (236) was markedly reduced when compared to 146 
the IL-6-dependent induction of transcripts in CD4+ TN cells (509) (Fig. 2e). The inclusion of anti-147 
CD3+CD28 co-stimulatory antibodies further suppressed the number of genes induced by IL-6 in CD4+ 148 
TEXP cells (26), indicating the capacity of TCR activation to replace the signal delivered by IL-6 (Fig. 2e and 149 
Supplementary Fig. 3d). Thus, IL-6 controls very distinct patterns of gene regulation in CD4+ TN, TEXP and 150 
TEM cells that may shape the functional properties of these CD4+ T cells. 151 
STAT1 phosphorylation is regulated by PTPN2  152 
We next determined whether TCR activation altered the expression of genes linked with IL-6 receptor 153 
signaling in CD4+ TN, TEXP and TEM cells. No significant differences in the expression of IL-6 receptor 154 
subunits (Il6ra, Il6st), Janus kinases (Jak1, Jak2, Tyk2), STATs (Stat1, Stat3, Stat5a, Stat5b) and regulators 155 
of IL-6 or Jak-STAT signaling (Socs1, Socs3, Pias1, Dusp2, Cish, Arid5a, Arid5b) were observed between 156 
these CD4+ T cells (Supplementary Fig. 4a). Thus, the immediate regulation of STAT1 activity in CD4+ TEXP 157 
cells and CD4+ TEM cells was not attributed to changes in the make-up of the IL-6 signaling cascade.  158 
To examine how CD4+ T cell activation affected STAT1 signaling we assessed IL-6 responses in wild-type 159 
CD4+ TN and TEM cells using antibodies for serine phosphorylated STAT1 and STAT3 (hereafter pS-STAT1 160 
and pS-STAT3). Intracellular flow cytometry showed that the IL-6 activation of pS-STAT1 and pS-STAT3 161 
was comparable in both CD4+ T cells (Fig. 3a). However, CD4+ TEM cells showed suppressed pY-STAT1 in 162 
response to IL-6 (Fig. 3a and Supplementary Fig. 1c). We therefore addressed whether protein 163 
phosphatases controlled the tyrosine phosphorylation of STAT1. Treatment of CD4+ TN and TEM cells with 164 
the protein tyrosine phosphatase inhibitor sodium orthovanadate reversed the loss of pY-STAT1 165 
activation in IL-6-stimulated CD4+ TEM cells (Fig. 3a). IL-6 control of pY-STAT3 was unaltered by sodium 166 
orthovanadate (Fig. 3a). Analysis of Ahr, Il21, Socs3 and Stat3 expression in IL-6-treated CD4+ TEM cells 167 
showed that the inclusion of sodium orthovanadate reduced expression of Il21 and Socs3 (Fig. 3b). Thus, 168 
protein tyrosine phosphatase activity appears integral to the IL-6 control of STAT1 in CD4+ TEM cells.  169 
To identify protein tyrosine phosphatases responsible for the regulation of STAT1 in CD4+ TEXP and TEM 170 
cells we compared transcriptomic data from CD4+ TN, TEXP and TEM cells activated with anti-CD3+CD28 co-171 
stimulatory antibodies. Several protein phosphatases were more highly expressed in CD4+ TEXP and TEM 172 
cells than CD4+ TN cells, and included the protein tyrosine phosphatases Ptpn2 and Ptpn22 (Fig. 3c).  173 
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Flow cytometry showed that PTPN2 was more highly expressed in CD4+ TEM cells than CD4+ TN cells (Fig. 174 
4a). Il6ra-/- CD4+ TEM cells had comparable expression of PTPN2 to wild-type CD4+ TEM cells (Fig. 4b), 175 
indicating that PTPN2 expression was independent of IL-6 signaling. To confirm the relevance of these 176 
findings to pathology we conducted immunohistochemistry of joint tissue from wild-type mice with AIA. 177 
Synovial CD3+ T cells showed enhanced expression of PTPN2 and low pY-STAT1 staining (Fig. 4c). 178 
Similarly, flow cytometry of IL-6-stimulated CD4+ TEM cells revealed that PTPN2 expression correlated 179 
with suppression of pY-STAT1 (Fig. 4b, Supplementary Fig. 4b). We next investigated IL-6 signaling in 180 
CD4+ TN and TEXP cells from whole genome C57Bl/6 Ptpn22-/- mice and Lck-Cre Ptpn2fl/fl mice, which lack 181 
PTPN2 in CD4+ T cells. As controls we used IL-6-treated CD4+ TN and TEXP cells isolated from C57Bl/6 wild-182 
type mice (for PTPN22) or C57Bl/6 Ptpn2fl/fl littermates. IL-6 activated pY-STAT1 in both Lck-Cre Ptpn2fl/fl 183 
and Ptpn22-/- CD4+ TEXP cells (Fig. 4d). When compared to IL-6 stimulated CD4+ TEXP cells from Lck-Cre 184 
Ptpn2fl/fl mice, the recovery of pY-STAT1 activity in IL-6 treated Ptpn22-/- CD4+ TEXP cells was less obvious 185 
(Fig. 4d). This possibly reflected a lower expression of Ptpn22 in CD4+ TEXP cells (Fig. 3c). Thus, PTPN2 186 
acted as a repressor of IL-6-induced STAT1 tyrosine phosphorylation in activated CD4+ T cells. 187 
We next explored whether PTP activity affected the production of IL-17A and IL-21 in CD4+ TEM cells. 188 
Intracellular flow cytometry indicated that Lck-Cre Ptpn2fl/fl and Ptpn22-/- CD4+ TEM cells mice generated 189 
less IL-17A and IL-21 than CD4+ TEM cells from Ptpn2fl/fl littermates or wild-type mice (Fig. 4e, 190 
Supplementary Fig. 4c). Moreover, ImageStream analysis showed the co-localization of PTPN2 with non-191 
phosphorylated STAT1 in wild-type CD4+ TEM cells (Fig. 4f). Thus, PTPN2, and to a lesser extent PTPN22, 192 
regulated STAT1 signaling in activated and memory CD4+ T cells. 193 
T cell activation re-tunes the transcriptional output of IL-6 in CD4+ TEM cells 194 
Next, we compared the transcriptional output of IL-6 in CD4+ TN, TEXP and TEM cells. Analysis was confined 195 
to significantly regulated genes (p<0.05) that displayed both a relative signal intensity of >150 and >1.5 196 
fold alteration in expression. Circos visualization identified a number of genes that were under IL-6 197 
control in CD4+ TN (225), TEXP (31) and TEM (180) cells (Fig. 5a). Hierarchical clustering and validation of 198 
selected gene targets identified IL-6 gene signatures that were either common to all three CD4+ T cells or 199 
uniquely expressed by a particular population (Supplementary Fig. 3c). Genes regulated by IL-6 in CD4+ 200 
TN, TEXP and TEM cells were mainly STAT3 target genes23, 24 and included genes that encoded 201 
transcriptional regulators (e.g., Bcl3, Bcl6, Etv6), co-repressors (e.g., Sbno2, Muc1) and negative 202 
regulators (e.g., Socs3, Pim1, Batf) of transcription factors such as STAT3, NF-κB and AP1 (Supplementary 203 
Fig. 3c). 204 
Next, we conducted a molecular pathway analysis of the transcriptomic data from IL-6-treated CD4+ TN, 205 
TEXP and TEM cells (Fig. 5b). We also mapped these datasets against publicly-available transcriptomic data 206 
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from IL-6-stimulated Stat1-/- and Stat3-/- CD4+ T cells (Fig. 5c)20. This analysis identified a series of STAT1-207 
regulated genes commonly associated with interferon (e.g., Irf8, Gbp2, Gbp5, Gbp6, Stat1, Parp9). In 208 
contrast, STAT3-regulated genes displayed greater functional diversity and were implicated in interleukin 209 
signaling, immune activation, proliferation, catabolism and metabolism (e.g., Socs3, Bcl3, Il6r, Kat2b) 210 
(Fig. 5b,c). This collective approach demonstrated that STAT1 and STAT3 regulated very distinct patterns 211 
of gene expression in IL-6 stimulated CD4+ TN, TEXP and TEM cells (Fig. 5b,c). For example, when compared 212 
with IL-6 stimulated CD4+ TN cells, activation with IL-6 enhanced the expression of genes associated with 213 
prolonged lymphocyte survival and memory (e.g., Hmox1, Myc, Cd83), and regulatory (e.g., Lag3, Il10, 214 
Foxp3) or effector (e.g., Ahr, Il21, Ifng) characteristics in CD4+ TEM cells.  215 
We next performed ChIP-seq in IL-6-stimulated CD4+ TN and TEM cells. Sequencing peaks displaying a 4-216 
fold increase above input (P<0.0001; FDR 0.05) were aligned to the genome and assigned to transcription 217 
start sites (TSS), exons and introns (Fig. 6 and Supplementary Fig. 5). Peaks located in undefined 218 
intergenic regions were excluded from the analysis. ChIP-seq of IL-6-stimulated CD4+ TN cells identified 219 
1625 peaks associated with STAT1 and 602 peaks for STAT3 (Fig. 6a). The number of STAT1 (446) and 220 
STAT3 (552) peaks was reduced in CD4+ TEM cells (Fig. 6a). To understand the regulatory properties of 221 
STAT1 and STAT3 we first confined our analysis to peaks residing within TSS regions (Fig. 6b and 222 
Supplementary Fig. 5). Sequencing peaks that mapped to defined gene promoters were correlated 223 
against corresponding transcriptomic data from IL-6-treated CD4+ TN and TEM cells (Fig. 6c and 224 
Supplementary Fig. 5). STAT1 and STAT3 showed substantially reduced binding to TSS regions in CD4+ TEM 225 
cells compared to CD4+ TN cells (Fig. 6b,c,d). Very few genes shared STAT1 and STAT3 binding (e.g., Stat3, 226 
Stat5b, Icam1, Socs3, Sigirr, and Akt2) (Fig. 6b,d), and these co-regulated genes were largely restricted to 227 
CD4+ TN cells (Fig 6b,d). Stat3 was the only gene that was bound by both STAT1 and STAT3 in CD4+ TEM 228 
cells (Fig. 6c). To determine the specificity of these DNA-transcription factor interactions we used 229 
computational tools to identify consensus DNA motifs for STAT1 and STAT3 binding (Supplementary Fig. 230 
5c). Analysis of ChIP-seq datasets from IL-6-treated CD4+ TN and TEM cells identified sequences resembling 231 
an IFN-regulated STAT responsive element (ISRE; E-value 5.9e-040) for STAT1 binding, and sequences 232 
homologous to a gamma-activated sequence (GAS; E-value 1.2e-115) for STAT3 (Supplementary Fig. 5c). 233 
We also identified consensus motifs for other transcription factors including SP1 and C2H2 Zn-finger 234 
transcription factor proteins (Supplementary Fig. 5c) and ChIP-qPCR showed STAT1 and STAT3 bound to 235 
SP1 consensus binding sequences (Supplementary Fig. 5d and Supplementary Table 2). Thus, 236 
transcriptional differences between IL-6 stimulated CD4+ TN and TEM cells are shaped by STAT1 and STAT3 237 
docking to both classical STAT-responsive elements and DNA motifs that suggested a regulatory interplay 238 
with other transcription factors in CD4+ TN and TEM cells. 239 
Genes under IL-6 control in CD4+ TEM cells are regulated at distal promoter regions  240 
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Next we investigated the canonical pathways associated with the genes that were bound with STAT1 or 241 
STAT3 in IL-6-treated CD4+ TN and TEM cells. Bioinformatic analysis identified a selective enrichment of 242 
genes involved in disease processes, catabolism and cytokine signaling in CD4+ TEM cells as compared to 243 
CD4+ TN cells (Supplementary Fig. 6a and Supplementary Table 3). Many of the genes associated with 244 
these pathways were distinct from those showing STAT1 or STAT3 binding to TSS (Fig. 6b), suggesting 245 
that genes under IL-6 regulation in CD4+ TEM cells may be controlled by STAT1 and STAT3 binding to distal 246 
promoter regions. To identify possible mechanisms that may explain this distal regulation we evaluated 247 
whether STAT1 and STAT3 peaks aligned with enhancer regions displaying enriched binding of the 248 
histone acetyl-transferase P300 (hereafter P300 enhancer elements25, 26, 27, 28). STAT1 and STAT3 ChIP-seq 249 
datasets from IL-6-treated CD4+ TN or TEM cells were mapped against publicly-available P300 ChIP-seq 250 
data from mouse CD4+ T cells polarized in vitro into TH1, TH2 or TH17 cells28 (Supplementary Fig. 6b and 251 
Supplementary Table 4). A combined analysis of IL-6-treated CD4+ TN and TEM cells identified 558 genes 252 
that bound P300 in association with either STAT1 or STAT3 (Fig. 7a,b). In IL-6-stimulated CD4+ TN and TEM 253 
cells we identified 215 genes that displayed alternate binding of STAT1 or STAT3 in CD4+ TN and TEM cells 254 
(Fig. 7b). These genes were selectively induced or repressed by IL-6 in CD4+ TEM cells (Fig. 7b, 255 
Supplementary Table 5). Among these, 208 genes aligned with genes bound by P300 in TH17 cells28. 256 
These included genes linked with proliferation and survival (e.g., Vmp1, Rbpj, Fasl), immune regulation 257 
(e.g., Cd200, Cish, Ctla4, Cd69), alternate lineage fates (e.g., Ahr, Batf, Bcl6, Cxcr5, Etv6, Fosl2, Irf4, Stat3) 258 
or differences in T cell effector function (e.g., Il10, Il21, Il4ra, Il17a, Il17ra, Il21r) (Supplementary Table 5). 259 
This analysis indicated that genes controlled by IL-6 in CD4+ TN and TEM cells are associated with P300 260 
enhancer elements that are potentially activated or suppressed by changes in the pattern of STAT1 or 261 
STAT3 binding. 262 
Among the 215 genes regulated by IL-6 in CD4+ TEM cells, 80 displayed STAT1 or STAT3 binding in ChIP-seq 263 
data from IL-6 activated CD4+ TN cells, but not in IL-6 treated CD4+ TEM cells (Fig. 7c). This suggested that 264 
the binding of these transcription factors to these sites acted as repressors of gene activation. ChIP-seq 265 
analysis of the other 135 genes showed that some form of STAT1 or STAT3 binding to P300 enhancer 266 
elements was retained in both IL-6 stimulated CD4+ TN and TEM cells (Fig. 7c and Supplementary Fig. 6b). 267 
These included Il10, Il21, Il21r, Bcl3, Batf, Junb, Socs1 and Cd274 (Fig.7c). Circos visualization illustrated 268 
how the binding of STAT1 and STAT3 to these promoters differed between IL-6 stimulated CD4+ TN and 269 
TEM cells (Fig. 7c). We identified 5 discrete patterns of STAT1 and STAT3 binding – pattern 1 (CD4+ TN cells: 270 
no STAT binding; TEM cells: STAT1), pattern 2 (CD4+ TN cells: STAT1, STAT3; TEM cells: STAT3), pattern 3 271 
(CD4+ TN cells: STAT3; TEM cells: STAT3), pattern 4 (CD4+ TN cells: STAT1; TEM cells: STAT3) and pattern 5 272 
(CD4+ TN cells: no STAT binding; TEM cells: STAT3) (Fig.7d). Computational analysis of the genes affiliated 273 
to each pattern revealed links with the cytokine control of T cell proliferation, differentiation and survival 274 
(Fig. 7d, Supplementary Fig. 6b and Supplementary Table 6). This was particularly apparent in pattern 2, 275 
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and to a lesser extent, pattern 3 and 5. Promoter regions assigned to pattern 2 displayed binding of 276 
STAT1 and STAT3 in IL-6 stimulated CD4+ TN cells, but showed a loss of STAT1 in IL-6 activated CD4+ TEM 277 
cells. Genes identified with this form of STAT regulation included Junb, Il4ra, Cd274 and Socs1 (Fig.7c and 278 
Supplementary Fig.6b) and suggested a potential link to the PTPN2-regulated of pY-STAT1. We therefore 279 
conducted a ChIP-qPCR analysis of STAT1 binding to the promoters of Junb, Il4ra, Cd274 and Socs1 in 280 
IL-6-stimulated Lck-Cre Ptpn2fl/fl and Ptpn2fl/fl CD4+ TEM cells. STAT1 binding to these promoters was 281 
specifically enriched in DNA samples from Lck-Cre Ptpn2fl/flCD4+ TEM cells as compared to control Ptpn2fl/fl 282 
CD4+ TEM cells (Fig. 7e). In contrast, the binding of STAT1 to the TSS regions of Stat3 and Irf1 remained 283 
unaltered, and DNA samples from Lck-Cre Ptpn2fl/flCD4+ TEM cells and control Ptpn2fl/fl CD4+ TEM cells 284 
showed similar enrichment for STAT1 (Fig. 7e). Thus, PTPN2 activity determined STAT1 binding to specific 285 
gene promoter regions in IL-6 activated CD4+ TEM cells. 286 
PTPN2 correlates with indices of synovial pathology in rheumatoid arthritis patients  287 
Many of the genes identified in IL-6 stimulated CD4+ TEM cells contribute to the generation and 288 
maintenance of effector T cells associated with autoimmunity (Supplementary Table 6). We therefore 289 
investigated the relationship between PTPN2 and PTPN22 and these IL-6-regulated genes in RNA-seq 290 
datasets from synovial tissues biopsies of 87 patients with rheumatoid arthritis. Expression of PTPN2 and 291 
PTPN22 in these biopsy samples was compared against corresponding histological staining of the 292 
inflamed synovium for the lymphocyte markers CD3 and CD20 by immunohistochemistry. Analysis 293 
revealed a close correlation between PTPN2 and CD3 and CD20 (Fig 8a). This association was particularly 294 
evident in synovial biopsies displaying evidence of ectopic lymphoid-like structures (lymphoid-rich) and 295 
synovitis with a prominent mononuclear cell infiltrate (myeloid-rich) (Fig. 8b)29. In contrast, PTPN22 296 
displayed a more uniform pattern of expression within the inflamed synovium and showed no 297 
correlation with lymphocyte markers or the type of synovial pathology (Fig. 8a,b). To establish a possible 298 
link between PTPN2 and the synovial expression of genes controlled by IL-6 in activated or memory CD4+ 299 
T cells PTPN2 was compared against the synovial expression of IL21, IL17A, CD274 and SOCS1. Analysis of 300 
synovial RNA-seq datasets showed a correlation between PTPN2 and IL21, IL17A, CD274 and SOCS1 (Fig. 301 
8c). This relationship was particularly evident in both lymphoid-rich and myeloid-rich synovitis (Fig. 8c). 302 
No clear correlation was observed between PTPN22 and these inflammatory markers (Fig. 8c). Thus, in 303 
human synovial pathology, PTPN2 associates with the involvement of lymphocytes in the disease process 304 
and corresponds with the expression of several inflammatory mediators linked to the regulation of 305 
STAT1 by PTP enzymes.   306 
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Discussion 307 
Through analysis of Jak-STAT signalling in CD4+ TN and TEM cells we identified that protein tyrosine 308 
phosphatases induced as a response to CD4+ TN cell activation altered the transcriptional output of IL-6 in 309 
CD4+ TEM cells. Our investigation showed that inhibition of STAT1 phosphorylation by PTPN2 affected the 310 
expression of certain STAT-regulated target genes in activated or memory CD4+ T cells. Thus, protein 311 
tyrosine phosphatases have the capacity to modify the way particular T cell subsets sense and interpret 312 
common cytokine cues. Whilst the study focussed on the biology of IL-6, this mechanism may also shape 313 
the transcriptional output of other lymphokines in CD4+ T cells. 314 
Protein phosphatases including dual specificity protein phosphatases (DUSP) and protein tyrosine 315 
phosphatases (PTP) can regulate Jak-STAT signaling30, 31. For example, PTPN2 and PTPN11 control the 316 
phosphorylation of STAT1 in fibroblasts32, 33. We showed that protein tyrosine phosphatases restrained 317 
IL-6 signaling through STAT1 in activated and memory CD4+ T cells. Transcriptional profiling of PTP 318 
expression in CD4+ T cells identified several candidate enzymes that were induced following CD4+ TN 319 
activation, including PTPN2, PTPN22 and DUSP2. Because DUSP2 inhibits signaling through STAT3 and 320 
restricts TH17 differentiation30, we assessed whether PTPN2 and PTPN22 affected STAT1 321 
phosphorylation. PTPN2 and PTPN22 inhibited STAT1 activity, but had a less obvious impact on STAT3 322 
activity. This observation might indicate a physical interaction between these PTP and STAT1.   323 
PTPN2 and PTPN22 control various lymphocyte responses, and individuals with genetic polymorphisms 324 
in PTPN2 or PTPN22 frequently show increased susceptibility to autoimmune disease34, 35. The ability of 325 
PTPN2 and PTPN22 to control Jak-STAT signaling may contribute to these outcomes through the control 326 
of immune activation, tolerance and autoimmunity. Our data showed that synovial PTPN2 was highly 327 
expressed in lymphoid-rich synovitis. This form of joint pathology is defined by the presence of 328 
functional ectopic lymphoid aggregates within the inflamed synovium36. Significantly, PTPN2 has been 329 
linked with the regulation of follicular TH cells and the activation of T and B cell responses37, 38, 39, 40. Our 330 
investigation showed that PTPN2 controlled the expression of genes commonly associated with ectopic 331 
lymphoid-like structures. For example, PTPN2-control of STAT1 phosphorylation was shown to affect the 332 
transactivation of inflammatory cytokines (e.g., IL-17A, IL-21), transcription factors (e.g., Bcl6), immune 333 
checkpoint regulators (e.g., CD274) and homeostatic chemokine receptors (e.g., CXCR4, CXCR5) involved 334 
in the activity or spatial organization of lymphoid aggregates36. The gene signature identified through our 335 
screen may therefore predict the efficacy of adoptive immunotherapy and vaccination strategies, or 336 
response to biological drug therapies. 337 
ChIP-seq of STAT1 and STAT3 in IL-6-treated CD4+ TN and TEM cells showed that both transcription factors 338 
bound to consensus motifs for STAT proteins (e.g., ISRE, GAS), and sequences specific for other 339 
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transcription factors (e.g., SP1-like proteins)41, 42, 43, 44. While the binding of STATs to these genomic sites 340 
requires further analysis, our results suggested that the induction of PTPN2 in activated CD4+ T cells 341 
affected the expression of STAT-regulated genes controlled by P300 enhancer elements. Many of the 342 
genes associated with these enhancers were induced by IL-6 in CD4+ TEM cells and included genes 343 
commonly associated with TH1, TH2, TH17 or TFH cells27, 28. These activities fit with the capacity of IL-6 to 344 
govern CD4+ T cell memory4, 5, 45, 46. For example, IL-6 renders antigen-specific T cells refractory to 345 
suppression by regulatory T cells56, 57. However, IL-6 signaling is not critical for the generation or 346 
maintenance of CD4+ memory cells4, 6. Instead, our data revealed that IL-6 promotes the effector or 347 
functional characteristics of CD4+ TEM cells. This contrasts with the activities of IL-23, which regulates 348 
memory recall through the control of cell-cycle progression and proliferation7, 47, 48. Thus, PTPN2 control 349 
of STAT1 may support CD4+ T cell memory responses by shaping effector memory functions or 350 
prolonging lymphocyte survival. Such findings may be relevant to our understanding of how T cells 351 
become released from anergy and might explain how T cells become directed down a commitment 352 
pathway as a response to specific TCR antigens39, 49, 50.  353 
  354 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
13 
Acknowledgements 355 
This manuscript is dedicated in fond memory of J. Uceda Fernandez, a dearly loved friend and colleague 356 
who was tragically taken from us on the 29th August 2018. Remembered forever.  357 
Versus Arthritis (Reference 20770, 19796 awarded to SAJ, NMW & GWJ), Hoffmann la Roche (to SAJ), 358 
Kidney Research UK (to SAJ) and the National Health and Medical Research Council of Australia (to TT) 359 
provided grant support for this project. GWJ is recipient of a Versus Arthritis Career Development 360 
Fellowship (Reference 20305). JUF held a la Caixa PhD Studentship administered through the British 361 
Council, and BCC is supported by a PhD studentship from the Systems Immunity University Research 362 
Institute at Cardiff. JL is recipient of a Rutherford Fellowship Grant. Analysis of synovial tissues was 363 
conducted with support from the Medical Research Council (to CJP; Reference 36661) and the Versus 364 
Arthritis funded Experimental Arthritis Treatment Centre (to CJP; Reference 20022). PRT is recipient of a 365 
Wellcome Trust Investigator Award (107964/Z/15/Z) and receives funding through the UK Dementia 366 
Research Institute. Bioinformatic analysis was developed with support from the Systems Immunity 367 
University Research Institute in Cardiff. The authors would like to thank Yuka Kanno, Chris Hunter, 368 
Stephen Turner, Toshi Nakayama, Magdalena Czubala, Rachel Errington, Atsushi Onodera, Kiyoshi 369 
Hirahara and John O’Shea for their advice, constructive opinions and kind support. 370 
Author contributions 371 
SAJ, GWJ, ACF and JPT wrote the text and prepared the figures for the paper. All authors reviewed and 372 
approved the final manuscript draft. SAJ, GWJ, TT, NMW, CP, PRT, CJP, JPT, ACF designed the study. BCC, 373 
RA, ML, MJT, BS, ACF, JPT and NMW conducted bioinformatic, biostatistical, and molecular pathway 374 
analyses. Laboratory based studies were performed by JPT, ACF, FW, MJT, XL, JUF, ADS, JL, DH and DM. 375 
Competing interests 376 
SAJ has received funding support from Hoffman-La Roche, GlaxoSmithKline, Ferring Pharmaceuticals and 377 
NovImmune SA, and during the last 5 years he has acted as an advisory consultant for Roche, Chugai 378 
Pharmaceuticals, NovImmune SA, Genentech, Sanofi Regeneron, Johnson & Johnson, Janssen 379 
Pharmaceuticals, Eleven Biotherapeutics.  380 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
14 
References 381 
1. MacLeod, M.K., Kappler, J.W. & Marrack, P. Memory CD4 T cells: generation, reactivation and re-382 
assignment. Immunology 130, 10-15 (2010). 383 
 384 
2. O'Shea, J.J. et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. 385 
Annu Rev Med 66, 311-328 (2015). 386 
 387 
3. Hunter, C.A. & Jones, S.A. IL-6 as a keystone cytokine in health and disease. Nat Immunol 16, 388 
448-457 (2015). 389 
 390 
4. Nish, S.A. et al. T cell-intrinsic role of IL-6 signaling in primary and memory responses. Elife 3, 391 
e01949 (2014). 392 
 393 
5. Longhi, M.P. et al. Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS 394 
Pathog 4, e1000006 (2008). 395 
 396 
6. Strutt, T.M. et al. Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against 397 
Influenza. The Journal of Immunology (2016). 398 
 399 
7. Jones, G.W. et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for 400 
IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol 184, 2130-2139 (2010). 401 
 402 
8. Fielding, C.A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 403 
40, 40-50 (2014). 404 
 405 
9. Harker, J.A., Lewis, G.M., Mack, L. & Zuniga, E.I. Late interleukin-6 escalates T follicular helper cell 406 
responses and controls a chronic viral infection. Science 334, 825-829 (2011). 407 
 408 
10. Briso, E.M., Dienz, O. & Rincon, M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain 409 
shedding in activated CD4 T cells. J Immunol 180, 7102-7106 (2008). 410 
 411 
11. Teague, T.K. et al. Activation-induced inhibition of interleukin 6-mediated T cell survival and 412 
signal transducer and activator of transcription 1 signaling. J Exp Med 191, 915-926 (2000). 413 
 414 
12. Hong, C. et al. Interleukin-6 expands homeostatic space for peripheral T cells. Cytokine 64, 532-415 
540 (2013). 416 
 417 
13. Chtanova, T. et al. Identification of T cell-restricted genes, and signatures for different T cell 418 
responses, using a comprehensive collection of microarray datasets. J Immunol 175, 7837-7847 419 
(2005). 420 
 421 
14. Curnow, S.J. et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by 422 
IL-6/soluble IL-6 receptor trans-signaling. J Immunol 173, 5290-5297 (2004). 423 
 424 
15. Nowell, M.A. et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of 425 
experimental inflammatory arthritis. J Immunol 182, 613-622 (2009). 426 
 427 
16. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against 428 
apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis 429 
in vivo. Nat Med 6, 583-588 (2000). 430 
 431 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
15 
17. Liao, W., Lin, J.X., Wang, L., Li, P. & Leonard, W.J. Modulation of cytokine receptors by IL-2 432 
broadly regulates differentiation into helper T cell lineages. Nat Immunol 12, 551-559 (2011). 433 
 434 
18. Villarino, A.V., Kanno, Y. & O'Shea, J.J. Mechanisms and consequences of Jak-STAT signaling in 435 
the immune system. Nat Immunol 18, 374-384 (2017). 436 
 437 
19. Costa-Pereira, A.P. et al. Mutational switch of an IL-6 response to an interferon-gamma-like 438 
response. Proc Natl Acad Sci U S A 99, 8043-8047 (2002). 439 
 440 
20. Hirahara, K. et al. Asymmetric Action of STAT Transcription Factors Drives Transcriptional 441 
Outputs and Cytokine Specificity. Immunity 42, 877-889 (2015). 442 
 443 
21. Peters, A. et al. IL-27 Induces Th17 Differentiation in the Absence of STAT1 Signaling. J Immunol 444 
195, 4144-4153 (2015). 445 
 446 
22. Jones, G.W. et al. Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling 447 
is independent of IL-17A. Ann Rheum Dis 72, 1738-1742 (2013). 448 
 449 
23. Anderson, A.E. et al. IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for 450 
early anticitrullinated peptide antibody-negative rheumatoid arthritis. Ann Rheum Dis 75, 466-451 
473 (2016). 452 
 453 
24. Pratt, A.G. et al. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 454 
6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. 455 
Ann Rheum Dis 71, 1374-1381 (2012). 456 
 457 
25. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 458 
(2013). 459 
 460 
26. Whyte, W.A. et al. Master transcription factors and mediator establish super-enhancers at key 461 
cell identity genes. Cell 153, 307-319 (2013). 462 
 463 
27. Vahedi, G. et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. 464 
Nature 520, 558-562 (2015). 465 
 466 
28. Ciofani, M. et al. A validated regulatory network for Th17 cell specification. Cell 151, 289-303 467 
(2012). 468 
 469 
29. Humby, F. et al. Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques 470 
by the OMERACT Filter--Determining Validation Requirements. J Rheumatol 43, 208-213 (2016). 471 
 472 
30. Lu, D. et al. The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and 473 
regulates T17 differentiation. Nat Immunol (2015). 474 
 475 
31. Bohmer, F.D. & Friedrich, K. Protein tyrosine phosphatases as wardens of STAT signaling. 476 
JAKSTAT 3, e28087 (2014). 477 
 478 
32. ten Hoeve, J. et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 479 
22, 5662-5668 (2002). 480 
 481 
33. Wu, T.R. et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at 482 
both tyrosine and serine residues in nuclei. J Biol Chem 277, 47572-47580 (2002). 483 
 484 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
16 
34. Hinks, A. et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile 485 
idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. 486 
Arthritis Rheum 52, 1694-1699 (2005). 487 
 488 
35. Sharp, R.C., Abdulrahim, M., Naser, E.S. & Naser, S.A. Genetic Variations of PTPN2 and PTPN22: 489 
Role in the Pathogenesis of Type 1 Diabetes and Crohn's Disease. Front Cell Infect Microbiol 5, 95 490 
(2015). 491 
 492 
36. Pitzalis, C., Jones, G.W., Bombardieri, M. & Jones, S.A. Ectopic lymphoid-like structures in 493 
infection, cancer and autoimmunity. Nat Rev Immunol 14, 447-462 (2014). 494 
 495 
37. Wiede, F., Sacirbegovic, F., Leong, Y.A., Yu, D. & Tiganis, T. PTPN2-deficiency exacerbates T 496 
follicular helper cell and B cell responses and promotes the development of autoimmunity. J 497 
Autoimmun 76, 85-100 (2017). 498 
 499 
38. Wiede, F. et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain 500 
tolerance in mice. J Clin Invest 121, 4758-4774 (2011). 501 
 502 
39. Salmond, R.J., Brownlie, R.J., Morrison, V.L. & Zamoyska, R. The tyrosine phosphatase PTPN22 503 
discriminates weak self peptides from strong agonist TCR signals. Nat Immunol 15, 875-883 504 
(2014). 505 
 506 
40. Wiede, F., La Gruta, N.L. & Tiganis, T. PTPN2 attenuates T-cell lymphopenia-induced 507 
proliferation. Nat Commun 5, 3073 (2014). 508 
 509 
41. Look, D.C., Pelletier, M.R., Tidwell, R.M., Roswit, W.T. & Holtzman, M.J. Stat1 depends on 510 
transcriptional synergy with Sp1. J Biol Chem 270, 30264-30267 (1995). 511 
 512 
42. Cantwell, C.A., Sterneck, E. & Johnson, P.F. Interleukin-6-specific activation of the C/EBPdelta 513 
gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol 18, 2108-2117 (1998). 514 
 515 
43. Zhang, Z., Jones, S., Hagood, J.S., Fuentes, N.L. & Fuller, G.M. STAT3 acts as a co-activator of 516 
glucocorticoid receptor signaling. J Biol Chem 272, 30607-30610 (1997). 517 
 518 
44. Zhu, M., John, S., Berg, M. & Leonard, W.J. Functional association of Nmi with Stat5 and Stat1 in 519 
IL-2- and IFNgamma-mediated signaling. Cell 96, 121-130 (1999). 520 
 521 
45. Kasahara, Y. et al. Role of interleukin 6 for differential responsiveness of naive and memory CD4+ 522 
T cells in CD2-mediated activation. J Exp Med 172, 1419-1424 (1990). 523 
 524 
46. Beagley, K.W. et al. Peyer's patch B cells with memory cell characteristics undergo terminal 525 
differentiation within 24 hours in response to interleukin-6. Cytokine 3, 107-116 (1991). 526 
 527 
47. Lee, Y.K. et al. Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92-107 528 
(2009). 529 
 530 
48. Haines, C.J. et al. Autoimmune memory T helper 17 cell function and expansion are dependent 531 
on interleukin-23. Cell Rep 3, 1378-1388 (2013). 532 
 533 
49. Mohrs, M., Lacy, D.A. & Locksley, R.M. Stat signals release activated naive Th cells from an 534 
anergic checkpoint. J Immunol 170, 1870-1876 (2003). 535 
 536 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
17 
50. van Panhuys, N., Klauschen, F. & Germain, R.N. T-cell-receptor-dependent signal intensity 537 
dominantly controls CD4(+) T cell polarization In Vivo. Immunity 41, 63-74 (2014). 538 
  539 
Twohig, Cardus Figueras, et al., 2019 
T cell activation re-tunes the signaling properties of IL-6 
18 
Figure Legends- 540 
Figure 1. Infiltrating T-cells showed impaired STAT1 activity in response to arthritis induction. (a) 541 
Representative H&E staining of knee joints at day 10 post disease induction (antigen-induced arthritis, 542 
AIA) (bar: 500μm); boxed area shows the location of the immunofluorescence. Representative 543 
immunofluorescence with antibodies against CD3 (red), pY-STAT1 or pY-STAT3 (green) is shown together 544 
with DAPI counterstaining (blue) (bar: 100μm). Graph shows the proportion of CD3+ T cells displaying 545 
either pY-STAT1 or pY-STAT3 (n=3). (b) Phosphorylation of STAT1 and STAT3 by flow cytometry of 546 
infiltrating synovial CD4+ T cells during AIA after stimulation with 20ng/ml IL-6 compare to CD4+ TN cells. 547 
(c) Representative flow cytometry of pY-STAT1 and pY-STAT3 in CD4+ T cells extracted from inguinal 548 
lymph nodes of mBSA challenged (n=4) and non-challenged mice (control) (n=3) following stimulation 549 
with 20ng/ml IL-6 for 30 min. Graphs show quantification of pY-STAT1 and pY-STAT3 activity in CD4+ TN 550 
and CD4+ TEM cells (n=4). (d) Quantitative PCR of Ahr, Ifng, Il17a, Il21, Rorc, Socs3 and Stat3 in CD4+ TN 551 
(n=4) and CD4+ TEM cells (n=2) extracted from inguinal lymph nodes of mBSA challenged mice. (e) 552 
Intracellular flow cytometry analysis of IL-21 production in CD4+ TN and CD4+ TEM cells extracted from 553 
inguinal lymph nodes after 4 hours stimulation with PMA, ionomycin and monensin (n=4). Data are 554 
representative of three independent experiments (c,e), two independent experiments (a,b) and one 555 
experiment involving biological replicates (d). ****P<0.0001, **P<0.01, *P<0.05 (Two-tailed unpaired 556 
Student’s t test (a,b,d,e) and one-way ANOVA test with Tukey's multiple comparison test (c). Data are 557 
shown as mean ± s.d.)  558 
 559 
Figure 2. CD4+ T cell subsets show different response to IL-6. (a) Representative flow cytometry analysis 560 
of STAT1 and STAT3 responses in naïve (TN), central memory (TCM), effector (TEff) and effector memory 561 
(TEM) CD4+ T cells after 30 min IL-6 stimulation (20ng/ml). Numbers indicate the percentage of pY-STAT1 562 
or pY-STAT3 staining. Temporal changes in pY-STAT1 and pY-STAT3 are shown for each T cell subset 563 
following IL-6 stimulation (n=3). (b) Detection of pY-STAT1 and pY-STAT3 in CD4+ TN, CD4+ TCM, CD4+ TEff 564 
and CD4+ TEM cells from WT and IL6ra-/- mice. CD4+ T cells were stimulated for 30 min with an equimolar 565 
concentration of IL-6 or an IL-6-sIL-6R fusion protein (HDS) (n=3). (c) Intracellular flow cytometry analysis 566 
of pY-STAT1 in CD4+ T cells following 30 min stimulation with IL-6, IL-27 or IFNγ (20ng/ml) (n=3). (d) 567 
Microarray expression data is presented for CD4+ TN (n=3), CD4+ TEM (n=3), and in vitro expanded CD4+ 568 
effector-like T cells (See Supplementary Fig.2a, CD4+ TEXP) (n=4) treated with 20ng/ml IL-6 for 6 hours. 569 
Analysis was confined to genes displaying both a relative signal intensity of >150 and >1.5-fold alteration 570 
in expression following IL-6 treatment (P<0.05). Heat map is hierarchically clustered based in the relative 571 
expression (Z-score) (left panel) or Fold change (right panel). (e) Volcano plots displaying IL-6 regulated 572 
gene expression in CD4+ TN and CD4+ TEXP cells stimulated with IL-6 (20ng/ml) or in combination with 573 
antibodies against CD3 and CD28. An interactive figure can be found on-line (http://jones-574 
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cytokinelab.co.uk/NI2019/figure2d.shtml). Data are representative of two independent experiments 575 
(a,c) and one experiment involving biological replicates (b,d,e). ***P<0.001 *P<0.05 (Two-tailed unpaired 576 
Student’s t test (a) and one-way ANOVA with Tukey's multiple comparison test (b,c). Data are shown as 577 
mean ± s.e.m). 578 
 579 
Figure 3. Induction of protein tyrosine phosphatases following T-cell activation limits STAT1 signalling. 580 
(a) CD4+ TN and CD4+ TEM cells were pre-treated for 5 min with 5mM sodium orthovanadate (vanadate) 581 
prior to IL-6 (20ng/ml) stimulation for 30 min. Changes in pY-STAT1 and pY-STAT3 activity were 582 
monitored by intracellular flow cytometry (MFI). A comparable analysis of pS-STAT1 and pS-STAT3 is 583 
shown as a control (n=3). (b) Quantitative PCR for Ahr, Il21, Stat3 and Socs3 after vanadate pre-584 
treatment and 20ng/ml IL-6 stimulation in CD4+ TEM cells (n=3). (c) Heatmap analysis of Affymetrix 585 
transcriptomic data identifies the top 20 genes (P<0.05; relative signal intensity of >150; 1.5-fold 586 
alteration) associated with protein tyrosine phosphatase enzyme family. Data is presented as a 587 
hierarchical cluster using the average linkage method (row 1-pearson rank correlation). Data are 588 
representative of two independent experiment (a,b) and one experiment involving biological replicates 589 
(c). ***P<0.001; ** P<0.01 (one-way ANOVA with Tukey's multiple comparison test (a) and two-way 590 
ANOVA with Sidak multiple comparison test (b). Data are shown as mean ± s.e.m (a) and mean ± s.d (b). 591 
 592 
Figure 4. STAT1 activity is regulated by PTPN2. (a) Representative histogram of PTPN2 staining in CD4+ 593 
TN and CD4+ TEM cells by flow cytometry. (b) Flow cytometry analysis of STAT1 phosphorylation and 594 
PTPN2 expression in CD4+ TN and CD4+ TEM cells analyzed 30 min after stimulation with 20 ng/ml IL-6. (c) 595 
Immunohistochemistry of the inflamed synovium from wild-type mice with antigen-induced arthritis 596 
(day-10 post disease induction) in tissue sections stained with antibodies against CD3, Ptpn2 and 597 
pY-STAT1. Scale bar, 100μm (left panel) and 200μm (right panel). (d) Analysis of pY-STAT1 and pY-STAT3 598 
in CD4+ TN and CD4+ TEXP cells derived from Ptpn2fl/fl, Lck-Cre Ptpn2fl/fl (left panel) or wild-type and 599 
Ptpn22-/- mice (right panel) (n=4) exposed to IL-6 (20 ng/ml) for 30 min in combination with antibodies 600 
against CD3 and CD28. Fold change relative to the untreated controls are compared. (e) IL-21 and IL-17A 601 
quantification by flow cytometry in CD4+ TEM cells from Ptpn2fl/fl and Lck-Cre Ptpn2fl/fl mice (n=3). (f) 602 
ImageStream analysis of STAT1 and PTPN2 localization in CD4+ TN and CD4+ TEM cells stained with 603 
antibodies against STAT1, pY-STAT1, PTPN2 and CD4. Data are representative of three independent 604 
experiments (a,b), two independent experiments (f) and one experiment involving biological replicates 605 
(c,d,e). ****P<0.0001; *** P<0.001 (One-way ANOVA with Tukey's multiple comparison test (d) and 606 
Two-tailed unpaired Student’s test (e). Data are shown as mean ± s.d.).  607 
 608 
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Figure 5. Transcriptomic analysis of IL-6 responses in CD4+ T cells. (a) Circos visualisation details the IL-6 609 
regulated gene changes in CD4+ TN and CD4+ TEXP cells (See Supplemental Figure-2), and ex vivo sorted 610 
CD4+ TEM cells. Total number of IL-6 regulated genes is presented in parenthesis for each population (P< 611 
0.05, Chip Intensity 150+, and > 1.5-fold change). Lines coloured in red represent up-regulated genes and 612 
all down-regulated gene changes are blue. Connecting lines highlight common genes that are IL-6 613 
regulated in two or more of the populations. (b) IPA analysis of genes associated with IL-6, STAT1 and 614 
STAT3 upstream regulators. Top left heat map shows the predicted activated state (orange) and the 615 
predicted inhibited state (blue) of transcription regulators. Upstream regulator analysis for CTLA4 and 616 
CD3 are presented as controls. Relative expression heat maps are presented as a hierarchical cluster 617 
using the average linkage method (row 1-pearson rank correlation). The differential expression of genes 618 
being regulated by IL-6, STAT1 or STAT3 is shown for CD4+ TN, CD4+ TEXP and CD4+ TEM cells. (c) IL-6 619 
regulated gene changes derived from transcriptomic analysis were directly compared with datasets 620 
derived from IL-6 stimulated Stat1-/- and Stat3-/- CD4+ T cells (GSE65621).  621 
 622 
Figure 6. ChIP-seq analysis of STAT1 and STAT3 binding in IL-6 stimulated CD4+ T cells. ChIP-seq was 623 
performed on genomic DNA extracted from sorted CD4+ TN and CD4+ TEM cells following 1-hour 624 
stimulation with IL-6 in presence of antibodies against CD3 and CD28. Peak calling and downstream data 625 
processing are described in Materials & Methods. (a) Pie charts show the proportion of peaks associated 626 
with STAT1 and STAT3 binding to defined genomic regions. The total number of peaks identified is 627 
displayed graphically. All datasets residing outside TSS regions were only included if located to exonic or 628 
intronic sites. (b) Analysis of gene clusters regulated by binding STAT1 and STAT3 in TSS promoter 629 
regions. The heat map shows the score value for each gene identified with Homer for STAT1 and STAT3 630 
ChIP-seq data in CD4+ TN (blue) and CD4+ TEM (red) cells. (c) Comparison of ChIP-seq datasets against 631 
Affymetrix gene expression (relative significance; -(log10 (adjusted P-value)). Analysis of STAT1 and 632 
STAT3 datasets is shown for CD4+ TN (blue) and CD4+ TEM (red) subsets. An interactive figure of additional 633 
information can be found on-line (http://jones-cytokinelab.co.uk/NI2019/figure6c.shtml) (d) Circos 634 
visualization of STAT1 and STAT3 binding to TSS regions of genes under IL-6 regulation in CD4+ TN and 635 
CD4+ TEM cells. Connecting lines are color coded to reflect involvement of STAT1 (green), STAT3 (blue) or 636 
both STAT1 and STAT3 (orange). 637 
    638 
Figure 7. IL-6 regulates the interaction of STAT1 and STAT3 with P300 enhancer sites. (a) Circos plot 639 
shows the co-localisation of STAT1 (blue) and STAT3 (orange) binding to genomic regions sharing P300 640 
enrichment in CD4+ TN and CD4+ TEM cells. The connecting lines show the relationship of STAT1 and STAT3 641 
binding between CD4+ TN and CD4+ TEM cells. P300 ChIP-seq datasets (Accession number GSE40463, 642 
GSE60482) are derived from TH1, TH2 and TH17 cells. (b) Heat map showing the expression of all IL-6 643 
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regulated genes linked with P300 binding in CD4+ TN and CD4+ TEM cells (positioned left). The 644 
correspondingly aligned heatmap (positioned right) shows the relationship to P300 sites in TH1, TH2 and 645 
TH17 cells and shows the number of clustered P300 sites affiliated to an individual gene (blue=0, 646 
yellow=4). Specific examples of individual genes are shown. (c) Circos visualisation of 135 genes that 647 
display P300 binding in association with either STAT1 or STAT3 in CD4+ TN versus CD4+ TEM cells. (d) IPA 648 
predictions of the five distinct patterns of STAT binding identified from panel c. Hierarchical clustering of 649 
canonical pathways was performed using -Log (P-value). Supplemental Table 6 lists the canonical 650 
pathways represented in the heatmap. (e) STAT1 binding enrichment quantification by ChIP-qPCR in 651 
Ptpn2fl/fl and Lck-Cre:Ptpn2fl/fl CD4+ TEM cells (one experiment with pool samples from 12 Ptpn2fl/fl and 8 652 
Lck-Cre Ptpn2fl/fl mice). 653 
 654 
Figure 8. Association of PTPN2 with rheumatoid arthritis. (a) Correlations of PTPN2 and PTPN22 with 655 
lymphocyte cell markers CD3 and CD20 (left). (b) Distribution of PTPN2 and PTPN22 in patients stratified 656 
according synovial pathology (lymphoid – blue, myeloid – red and fibroid – green) (right). (c) Pearson 657 
correlations of synovium PTPN2 and PTPN22 with inflammatory markers including IL21, IL17A, CD274 658 
and SOCS1 in lymphoid (blue), myeloid (red) and fibroid (green) phenotypes. P values were adjusted 659 
using false discovery rate (FDR) correction (Benjamini-Hochberg). 660 
  661 
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Materials and methods- 662 
Recombinant Cytokines- Recombinant mouse IL-6 (IL-6), IL-27, IL-10, IL-7 and IFNγ were purchased from 663 
R&D Systems. The IL-6-sIL-6R fusion protein HDS (Mw: 63.5kDa) was expressed in CHO cells and purified 664 
through a partnership with the CRO Biovian OY (Turku, Finland). HDS was engineered by coupling the 665 
entire coding sequence (amino acid residues 1-364) for the differentially-spliced variant of human IL-6R 666 
(containing the unique COOH-terminal amino acid sequence: GSRRRGSCGL) to IL-6 (amino acid residues 667 
29-212) via a flexible glycine-serine rich linker sequence (single amino sequence: GGGGSGGGGSLE)8.  668 
Antibodies- Mouse specific antibodies against CD3ε/γ (17A2; Biolegend), CD4 (RM4-5; eBioscience), 669 
CD25 (PC61.5; eBioscience), CD44 (IM7; BD Biosciences), CD62L (MEL-14; Life Technologies), CD126 670 
(D7715A7; eBioscience), CD127 (25-1271-82; eBioscience), βTCR (H57-597), gp130 (125623; R&D 671 
Systems), IFNγ (XMG1.2; eBioscience), IL-4 (11B11; eBioscience), IL-17A (TC11-18H10.1; Biolegend), IL-21 672 
(Recombinant mouse IL-21R Fc Chimera protein; R&D and IL-21 receptor antibody; Jackson Immuno 673 
Research) and PTPN2 (AF1930; R&D) were used. For detection of human antigens, we used antibodies 674 
specific to CD3 (UCHT1; BioLegend), CD4 (RPA-T4; eBioscience), CD45RA (HI100; BioLegend), CD45RO 675 
(UCHL1; BioLegend), CD62L (DREG-56; BD Biosciences), CD197 (CCR7; G043H7; BioLegend). Human and 676 
mouse cross-specific antibodies to pY-STAT1 (pY701; 4a), pY-STAT3 (pY705; 4/P-STAT3), pS-STAT1 677 
(pS727; K51-856) and pS-STAT3 (pS727, 49/p-Stat3) were from BD Biosciences.  678 
Mice- Inbred wild type C57BL/6 male mice were purchased from Charles River UK. C57BL/6 IL-6 receptor 679 
deficient mice (Cd126-/-) mice have been described previously and were bred under approved UK Home 680 
Office guidelines in Cardiff University7. Ptpn2fl/fl, Lck-Cre:Ptpn2fl/fl, and Ptpn22-/- mice were bred and 681 
housed at the Peter MacCallum Cancer Centre (Melbourne, Australia). All mice were 8-12 weeks of age. 682 
For T cell stimulation experiments eight-week-old male Lck-Cre;Ptpn2fl/fl mice and Ptpn2fl/fl littermate 683 
controls were used38. All procedures were performed in accordance with the NHMRC Australian Code of 684 
Practice for the Care and Use of Animals, and approved by the Peter MacCallum Animal Ethics and 685 
Experimentation Committee (Ethics number: AEEC 570). Antigen-induced arthritis was performed under 686 
the UK Home Office-approved project licences PPL 30/2928 and PB3E4EE13 as previously described51. 687 
Briefly, mice were immunized (s.c.) with 100 µl mBSA (1 mg/ml emulsified in Complete Freund’s 688 
Adjuvant; CFA) and 160 ng Bordetella pertussis toxin (i.p.) (all from Sigma-Aldrich). Mice were 689 
administered with mBSA and CFA (s.c.) one week later. Inflammatory arthritis was triggered 21 days 690 
following the initial immunization by intra-articular administration of mBSA (10 µl; 10 mg/ml) into the 691 
right knee joint. Animals were monitored daily for wellbeing and clinical signs of arthritis, and killed at 692 
indicated time points for evaluation of joint-infiltrating T cells by flow cytometry and 693 
immunofluorescence. For flow cytometric analysis of synovial CD4+ T cells, inflamed synovium was first 694 
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dissected and digested in Collagenase type IV (37˚C, 1 hour) before passing through a 40µm cell strainer 695 
to generate single cell suspensions.  696 
Human synovial samples- Synovial samples were acquired through a minimally invasive ultrasound-697 
guided synovial biopsy (see Reference52) from 87 patients presenting with early rheumatoid arthritis (RA) 698 
naïve to therapy from the Pathobiology of Early Arthritis Cohort (PEAC). Ethical approval was granted by 699 
the King's College Hospital Research Ethics Committee (REC 05/Q0703/198). Paraffin embedded sections 700 
(3μm) of each biopsy was stained with haematoxylin and eosin. Immune cell infiltration was determined 701 
in sequentially cut sections by staining for B-cells (CD20), T cells (CD3), macrophages (CD68) and plasma 702 
cells (CD138) as previously reported, categorising samples into Lympho-myeloid, Diffuse-Myeloid and 703 
Pauci-immune Fibroid pathotypes53. 704 
CD4+ T cell cultures- Murine CD4+ T cells were enriched by negative magnetic selection (Miltenyi Biotec) 705 
before purification of naïve (CD4+CD25−CD44loCD62LhiCD127hi), central memory 706 
(CD4+CD25−CD44hiCD62LhiCD127hi), effector (CD4+CD25−CD44loCD62LloCD127lo-int) or effector memory 707 
(CD4+CD25−CD44hiCD62LloCD127int-hi) T cells using a BD FACS ARIA II (BD Biosciences). T cell subset purity 708 
was >98%. Naïve CD4+ T cells were cultured in RPMI-1640 supplemented with 10% (v/v) FCS, 2mM L-709 
glutamine, 100U/ml penicillin, 100µg/ml streptomycin, 1mM sodium pyruvate and 50µM 2-710 
mercaptoethanol. 1 x 105 CD4 T cells were activated by plate bound anti-CD3 (1μg/ml; 145-2C11, R&D 711 
Systems) and soluble anti-CD28 (5μg/ml; 37.51, eBioscience). Where indicated, CD4+ T cells were rested 712 
for 48 hours in the absence of stimulatory antibodies or cytokines (see Supplementary Fig. 2a). CD4+ T 713 
cells from the inguinal lymph nodes of mBSA-immunized and non-immunized mice were derived using a 714 
CD4+ T cell isolation kit (Miltenyi Biotec) and treated with IL-6 for 30 min with anti-CD3/CD28 715 
stimulation. Human peripheral blood mononuclear cells (PBMC) were isolated from fresh whole blood as 716 
previously described54. Naïve (CD3+CD4+CD45ROloCD62LhiCCR7hi), central memory 717 
(CD3+CD4+CD45ROhiCD62LhiCCR7hi), effector (CD3+CD4+CD45ROloCD62LloCCR7lo) or effector memory 718 
(CD3+CD4+CD45ROhiCD62LloCCR7lo) CD4+ T cells were then purified using a BD FACS ARIA II (BD 719 
Biosciences). To investigate the involvement of protein tyrosine phosphatases CD4 T cells were pre-720 
treated (5 min) with 5mM sodium orthovanadate (New England BioLabs (UK) Ltd) prior to subsequent 721 
stimulation. 722 
Histological analysis- Formalin-fixed paraffin-embedded knee joints from AIA-challenged mice were 723 
prepared for immunofluorescent and immunohistochemical detection of antigens as described 724 
previously51. For immunofluorescence, sections were rehydrated and antigen retrieval performed in 725 
10mM sodium citrate buffer containing 0.05% (v:v) Tween 20 (95°C, 40 min). Sections were incubated 726 
with 10% (v:v) goat or swine serum appropriate to the secondary antibody. Cells positive for CD3 and 727 
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intracellular phospho-STAT1 and STAT3 were detected using CD3 (A0452, Dako), and pY-STAT1 (Tyr701; 728 
58D6) or pY-STAT3 (Tyr705; D3A7) specific antibodies from Cell Signaling Technologies. For CD3 staining, 729 
primary antibody detection was performed using biotinylated swine anti-rabbit IgG (E0431, Dako) with 730 
streptavidin-APC (BD Biosciences). For pY-STAT1 and pY-STAT3 detection a secondary rabbit anti-goat 731 
IgG Alexa Fluor 488 antibody (Life Technologies) was used. Slides were mounted with Prolong Gold 732 
Antifade with DAPI nuclear counterstain (Invitrogen). Images were collected using a Zeiss Apotome 733 
microscope and analyzed using ImageJ software. For immunohistochemistry, antigens were detected in 734 
paraffin sections using antibodies against CD3 (A0452, Dako), pY-STAT1 (Tyr701; 58D6) and PTPN2 735 
(AF1930, R&D Systems). Antigen retrieval was performed as above, and endogenous peroxidase activity 736 
blocked using 3% (v:v) H2O2. Antibody labelling was detected using biotinylated secondary antibodies 737 
(Dako, E0431), the Vectastain ABC kit and diaminobenzidine (Vector Laboratories). Sections were 738 
counterstained with haematoxylin. Images were collected using Leica DM 2000 Led and quantification of 739 
staining performed using the Leica QWin microscope imaging software.  740 
Flow cytometry- Analysis was performed as described previously7, 8, 15. For the intracellular detection of 741 
STAT1 and STAT3 phosphorylation, purified CD4+ T cells were fixed in 2% (w:v) paraformaldehyde for 15 742 
min at 37⁰C, followed by permeabilization in 90% (v:v) methanol at -20⁰C for 3hrs. Cells were stained for 743 
CD4 and phosphorylated STAT1, STAT3 7. To evaluate effector cytokine production, CD4+ T cells were 744 
stimulated with 50ng PMA (phorbol 12-Myristate 13-Acetate), 500ng ionomycin and 3μM monesin for 4 745 
hours prior to flow cytometric analysis7, 8, 15. Cells were acquired on a CyAn ADP analyzer (Beckman-746 
Coulter) and analysed using Summit (software v4.3, Beckman-Coulter) or FlowJo 10 (TreeStar). For 747 
imaging flow cytometry, cells were resuspended in 100 µl of PBS and acquired using the ImageStream 748 
imaging flow cytometer (Amnis). For co-localization analysis ImageStream software IDEAS (Amnis) was 749 
used.  750 
RNA purification and Q-PCR- For quantitative real-time PCR (Q-PCR), and Affymetrix gene chip analysis, 751 
total RNA was extracted from purified or cultured CD4 T cells using the RNeasy Mini Kit (Qiagen) and 752 
QIAshredders (Qiagen). Contaminating genomic DNA was removed by on-column DNase digestion 753 
(Qiagen). RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit with 754 
RNase Inhibitor kit (Life Technologies). Gene expression was determined by Q-PCR8, 55 using the 755 
QuantStudio 12K Flex Real-Time PCR system and the following TaqMan probes from Thermofisher: Ahr 756 
(Mm00478932_m1), Bcl3 (Mm00504306_m1 ), Bcl6 (Mm01342164_m1), Il10 (Mm00439614_m1), Il21 757 
(Mm00517640_m1), Irf1 (Mm01288580_m1), Socs3 (Mm00545913_s1), Stat3 (Mm01219775_m1), Pim1 758 
(Mm00435712_m1) and Actb (Mm01205647_g1) as a housekeeping gene. Relative mRNA expression 759 
was determined by the comparative cycle threshold (CT) method and normalised to the gene Actb.  760 
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Affymetrix microarray and transcriptomic analysis- Purification of high quality RNA (RNA integrity 761 
number >8.5) was confirmed using Agilent RNA Nano microfluidic chips using a 2100 Bioanalyzer 762 
Instrument (Agilent Technologies). Expression profiling was performed in triplicate using Affymetrix 763 
Mouse GeneChip® 2.0ST microarrays (Affymetrix). Single-stranded cDNA was synthesized using the 764 
Ambion® WT (Whole Transcript) Expression Kit with the Affymetrix® Genechip® Poly-A RNA Control Kit 765 
and Terminal Labelling kit. Arrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix). Raw 766 
Affymetrix data files (CEL files) were imported into an in-house analysis pipeline written in R (version 767 
3.1.1) using Bioconductor packages, namely limma, affy and oligo56, 57, 58, 59. Data were background 768 
corrected, log2 transformed and quantile normalized using the oligo package (RMA) “best practice”. 769 
Differentially expressed genes and transcripts were identified using the limma package “best practice” 770 
workflow and P-values were corrected by multiple testing using Benjamini-Hochberg (false discovery 771 
rate)57. 772 
Bespoke coding (Perl) (Code available on request) was used to unite data over all conditions. To identify 773 
differentially expressed genes over all experiments, we selected the genes that were classified as having 774 
altered expression (either decreasing or decreasing) by a difference of 1.5-fold or greater, with a 775 
significant value P≤0.05 and a minimal expression value of 150 relative intensity units. Only transcripts 776 
fulfilling all these selection criteria in three independent microarray experiments were included in the 777 
analysis. Files were also created in the input format required for molecular and pathway analysis using 778 
Metacore integrated software suite (Thomson Reuters)59 and Ingenuity Pathway Analysis (IPA, 779 
http://www.ingenuity.com/products/ipa). Transcriptome matrix visualization and hierarchical clustering 780 
were performed using Morpheus software (https://software.broadinstitute.org/morpheus/). Circos plot 781 
were obtained using the Circos software (http://circos.ca/software/)60. Networks were visualization and 782 
analysed using the open sourced program Gephi (0.9.1) (https://gephi.org/). Microarray data have been 783 
deposited in ArrayExpress under Accession code E-MTAB-7682. 784 
RNA-sequencing- Open access datasets from IL-6 treated Stat1-/- and Stat3-/- T cells (GSE65621) were 785 
obtained from GEO (https://www.ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house 786 
bioinformatic pipeline. Briefly, RNA-seq single-end fastq files were mapped to mouse assembly GRCm38 787 
using STAR61. Transcript counts were produced with FeatureCounts62 and data normalised using the 788 
Bioconductor package, DeSeq263 obtaining gene expression values as FPKM (Fragments Per Kilobase 789 
Million). 790 
For the human samples, RNA from homogenised synovial tissue was extracted in Trizol. 1μg total RNA 791 
was used as input material for library preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina). 792 
Generated libraries were amplified with 10 cycles of PCR. Library size was confirmed using 2200 793 
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TapeStation and High Sensitivity D1K screen tape (Agilent Technologies) and concentration was 794 
determined by Q-PCR based method using Library quantification kit (KAPA). Libraries were multiplexed 795 
(five per lane) and sequenced on Illumina HiSeq2500 (Illumina) to generate 50 million paired-end 75 base 796 
pair reads. Transcript abundance was derived using Kallisto v0.43.0 with GENCODE v24/GRCh38 as 797 
reference64. Transcript abundances were summarised over transcript isoforms using Bioconductor 798 
package tximport 1.4.0. Imported abundances were processed using DESeq2 1.14.1 and transformed as 799 
regularised log expression (RLE). Statistical analysis of gene-gene correlations was performed using 800 
Pearson correlation. P values were adjusted using false discovery rate (FDR) correction (Benjamini-801 
Hochberg). RNA-seq data have been deposited in ArrayExpress under Accession code E-MTAB-6141. 802 
Chromatin Immunoprecipitation (ChIP)-seq- STAT1 and STAT3 chromatin Immunoprecipitation was 803 
performed as previously described20. Briefly, 1x107 naïve (TN) and effector memory (TEM) CD4+ T cells 804 
were activated for 1h with 20ng/ml IL-6 in the presence of antibodies against CD3 and CD28 (as 805 
described earlier). Genomic DNA was extracted, cross-linked and fragmented by sonication prior to 806 
overnight incubation with 5ug of anti-STAT1 (sc-592, Santa Cruz Biotechnology) or anti-STAT3 (sc-482, 807 
Santa Cruz Biotechnology) antibodies. The quality of the immunoprecipitation was confirmed by ChIP-808 
qPCR for Irf1 and Socs3. To minimize systematic biases in the downstream data, an input reference 809 
control sample (chromatin taken before ChIP) was used to correct for genomic copy number variations, 810 
sonication-induced fragmentation bias, and chromatin accessibility. ChIP-seq libraries for Ion Torrent 811 
sequencing were prepared according to manufacturer’s instructions (# 4473623, Ion ChIP-Seq Library 812 
Preparation on the Ion Proton TM System). Briefly, DNA fragments were end-repaired and ligated to ion-813 
compatible adapters. Libraries were amplified and size-selected for insert lengths of approximately 100-814 
250bp. Between 40M to 70M reads were obtained for each sample and mapped to Murine Genome 815 
Build GRCm38 (mm10) using the Ion Proton recommended mapper, Bowtie265, 66. Reads were removed 816 
where mapping quality was less than q20 (phred score) and peaks called using HOMER (Hypergeometric 817 
Optimization of Motif EnRichment). To identify putative peaks in both ChIP and input, we first used 818 
HOMER findPeaks with a False Discovery Rate (FDR) value of 0.05. To identify sample peaks in the 819 
context of input, we then used HOMER findPeaks with the default parameters (Fold Change > 4-fold, P-820 
value < 0.0001). Peaks were visualised using Integrative Genomics Viewer (IGV 2.3.8867). Available p300 821 
ChIP-seq fastq files from CD4+ T cells, TH1, TH2 (GSE40463) and TH17 (GSE60482) were obtained from GEO 822 
(https://www.ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house pipeline. Reads were 823 
mapped to the same mm10 assembly using BWA. All reads with a mapping quality less than q20 were 824 
removed. HOMER isoftware was used to locate P300 enhancer elements (using the Homer option, –style 825 
super) and parameters Fold Change > 2-fold, P-value < 0.0001. To align STAT1 or STAT3 peaks with SE 826 
regions, overlapping loci identified by STAT1 and STAT3 ChIP-seq and p300 ChIP-seq were identified 827 
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using bedtools (http://bedtools.readthedocs.io/en/latest/)68. ChIP-Seq data have been deposited in 828 
ArrayExpress under Accession code E-MTAB-6273. 829 
ChIP-qPCR- To validate STAT-binding to promoter regions, Taqman custom assays were designed (see 830 
Supplementary Table 2 for oligonucleotide primer sequences) and qPCR performed using a QuantStudio 831 
12K Flex Real-Time PCR System. For analysis of SP1, chromatin immunoprecipitation was conducted as 832 
previously described using 5ug of SP1 antibody (#17-601, Millipore) or isotype specific IgG control. 833 
Analysis by qPCR used oligonucleotide primer sequences to the promoter regions of Irf1, Socs3, Stat3, 834 
Cd274, Il4ra, Junb and Socs1 (Supplementary Table 2). Specific enrichment was normalised by 835 
subtracting the IgG control values from those derived for the input and antibody specific 836 
immunoprecipitation samples. Value were expressed as 2^ΔCT.  837 
Motif finding- MEME Suite 4.11.2 software was used to discover de novo enriched DNA consensus 838 
sequences present in peaks identified within the STAT1 or STAT3 ChIP-seq datasets. All sequence 839 
predictions derived from MEME based on the interaction of known transcription factors with target DNA 840 
sequences where substantiated using STAMP69 (http://benoslab.pitt.edu/stamp/) and JASPAR database 841 
(http://jaspar.genereg.net/cgi-bin/jaspar_db.pl)70. 842 
Statistics- To determine the statistical significance of differences between data sets, Two-tailed unpaired 843 
Student’s t-test were performed when two populations were compared. One-way ANOVA followed 844 
Tukey’s comparison test was used for multiple comparisons, unless otherwise specified, conducted using 845 
GraphPad Prism 5 (GraphPad Software). Statistical significance is also highlighted with the following 846 
notations: *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001. P ≤ 0.05 was considered significantly 847 
different.  848 
Reporting Summary- Further information on experimental design is available in the Life Sciences 849 
Reporting Summary linked to this article. 850 
Data Availability- Microarray, ChiP-seq and RNA-seq data have been deposited in ArrayExpress under 851 
Accession code E-MTAB-7682, E-MTAB-6273 and E-MTAB-6141, respectively. Available p300 ChIP-seq 852 
fastq files from CD4 T cells, Th1, Th2 (GSE40463) and Th17 (GSE60482), and Stat1-/- and Stat3-/- T cells 853 
(GSE65621) were obtained from GEO (https://www.ncbi.nlm.nih.gov/geo/). Access to interactive data 854 
sets can be found at www.jones-cytokinelab.co.uk (see relevant Figure Legends for additional 855 
information).  856 
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